Arquivos do dia: Julho 12, 2021
[Preprint] Heparina para pacientes com Covid-19 moderada – “Em pacientes com Covid-19 moderada e D-dímero elevado, a terapia com heparina não reduziu significativamente o desfecho primário, mas reduziu as chances de morte em 28 dias de doença.”
12 Jul, 2021 | 11:41hHeparin for Moderately Ill Patients with Covid-19 – medRxiv
Relacionado: RCT: In patients hospitalized with Covid-19 with elevated D-Dimer, a full-dose anticoagulation strategy based on rivaroxaban (full-dose heparins in unstable patients) + rivaroxaban to day 30 was not better than prophylactic anticoagulation and increased bleeding risk. E [Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups. E [Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
Comentário no Twitter (fio – clique para saber mais)
🚨Final results of the RAPID trial now pub'd @medrxivpreprint 🚨 RAPID was an open-label trial that randomly assigned hospitalized ward patients with COVID-19 and elevated D-dimer levels to therapeutic or prophylactic heparin. 🧵 1/10 https://t.co/oxiyXQAPeK pic.twitter.com/V2GtruEyM2
— Michelle Sholzberg (@sholzberg) July 9, 2021
[Preprint] Estudo confirma o risco extremamente baixo de morte por Covid-19 em crianças – “99,995% das crianças e jovens com teste positivo para SARS-CoV-2 sobreviveram.”
12 Jul, 2021 | 11:39hComentários: Risks of severe illness in children from COVID-19 shown to be very low in largest study yet – University of Liverpool E Covid: Children’s extremely low risk confirmed by study – BBC
Estudo relacionado feito pelo mesmo grupo (preprint): Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS in England during the first pandemic year – medRxiv
Nova orientação do CDC para a prevenção da COVID-19 em escolas de educação infantil afirma que a prioridade é o retorno seguro ao ensino presencial.
12 Jul, 2021 | 11:38hComentários: Updated CDC schools guidance prioritizes in-person learning, even if all Covid-19 safety measures aren’t in place – CNN E The C.D.C. Issues New School Guidance, With Emphasis on Full Reopening – The New York Times E New CDC guidance says fully vaccinated teachers and students don’t need to wear masks indoors – CNBC E CDC calls for reopening schools fully, recommends masking – CIDRAP
Relacionado: COVID and schools: the evidence for reopening safely – Nature
Estudo randomizado | Outro estudo mostra que a azitromicina não melhora os desfechos em pacientes com Covid-19.
12 Jul, 2021 | 11:37hComentários: Trial shows that the antibiotic azithromycin does not prevent mild COVID cases progressing to hospitalization, death – European Society of Clinical Microbiology and Infectious Diseases E Azithromycin: can its benefit be ruled out in mild COVID-19? – The Lancet Respiratory Medicine
Relacionado: M-A: Azithromycin does not reduce the need for invasive mechanical ventilation or mortality in patients with Covid-19. E RCT: Azithromycin provides no benefit for community treatment of patients with suspected COVID-19 E RECOVERY trial: Azithromycin not beneficial for patients admitted to hospital with COVID-19 E E Coalition Covid-19 Brazil – Randomized trial: Azithromycin not beneficial for patients admitted to the hospital with severe Covid-19 E Coalition Covid-19 Brazil – Randomized trial: hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19
Comentário no Twitter
In patients with mild-to-mod #COVID19 managed without hospital admission, azithromycin + SOC did not reduce the risk of subsequent hospital admission or death
Read the ATOMIC2 trial here https://t.co/QXJ7T08JZS, being presented at #ECCMID2021 by lead author Tim Hinks @HinksLab pic.twitter.com/ZDiPhuQqFB
— The Lancet Respiratory Medicine (@LancetRespirMed) July 9, 2021
Pfizer afirma que é hora de um reforço (terceira dose) na vacina contra a Covid; FDA e CDC dizem que ainda não.
12 Jul, 2021 | 11:35hPfizer says it’s time for a Covid booster; FDA and CDC say not so fast – CNN
Ver também: CDC, FDA contradict Pfizer on COVID-19 vaccine booster – CIDRAP E Do I need a COVID-19 booster shot? 6 questions answered on how to stay protected – The Conversation E Pfizer suggests booster shots will be needed this year, but government officials say science will dictate the timing – The Washington Post E Pfizer to seek OK for 3rd vaccine dose; shots still protect – Associated Press E Citing the Delta Variant, Pfizer Will Pursue Booster Shots and a New Vaccine – The New York Times (poucos artigos gratuitos por mês) E Question open on need for COVID booster shot, data awaited, WHO says – Reuters
Public Health England | As vacinas contra COVID-19 são altamente eficazes em grupos de alto risco.
12 Jul, 2021 | 11:34hCOVID-19 vaccines highly effective in clinical risk groups – Public Health England
Comentário: Covid vaccines do work well in clinically vulnerable – BBC E Public Health England says Pfizer, AstraZeneca vaccines effective in high-risk groups – Reuters
Comentário no Twitter (fio – clique para saber mais)
NEWS: #COVID19 #vaccines highly effective in clinical risk groupshttps://t.co/mkVnxTqOrJ pic.twitter.com/M6Me98SRln
— Public Health England (@PHE_uk) July 9, 2021
Lambda, a mais nova variante de interesse da OMS, está agora em 29 países.
12 Jul, 2021 | 11:33hLambda, the Newest WHO Variant of Interest, is Now in 29 Countries – Health Policy Watch
É possível aplicar doses menores das vacinas já existentes contra a Covid para inocular mais pessoas? Os especialistas estão divididos.
12 Jul, 2021 | 11:32hCan we stretch existing Covid vaccines to inoculate more people? Experts are divided – STAT
Ver também: Quarter-dose of Moderna COVID vaccine still rouses a big immune response
Há necessidade urgente de um correlato de proteção para as vacinas contra o SARS-CoV-2 – “Estudos recentes sugerem que os anticorpos neutralizantes podem servir como um correlato de proteção para as vacinas contra o SARS-CoV-2 em humanos.”
12 Jul, 2021 | 11:31hA correlate of protection for SARS-CoV-2 vaccines is urgently needed – Nature Medicine
Relacionado: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection.
OMS afirma que os benefícios das vacinas de mRNA contra a COVID são superiores aos raros riscos cardíacos.
12 Jul, 2021 | 11:30hBenefits of mRNA COVID vaccines outweigh rare heart risks, says WHO – Reuters
Ver também: EU finds potential link between heart inflammation and mRNA COVID shots – Reuters E Heart inflammation link to Pfizer and Moderna jabs – BBC